1 results match your criteria: "Saint-Louis University Hospital Assistance Publique-Hôpitaux de Paris (AP-HP) Paris France.[Affiliation]"
A second autologous stem-cell transplantation (ASCT2) is considered for relapsed multiple myeloma (RMM) patients showing prolonged response after a first ASCT. However, given breakthrough treatments like anti-CD38 and immunotherapy, its role remains debated. We conducted a real-life study in 10 French centers (1996-2017) involving 267 RMM patients receiving ASCT2.
View Article and Find Full Text PDF